Abstract

BackgroundThough adherence to disease-modifying therapies (DMTs) among persons with multiple sclerosis (PwMS) varies and is often below 80%, only few prospective studies on adherence examined predictors beyond demographic and clinical characteristics.ObjectivesIdentify antecedents to adherence and persistence to DMT in a prospective design among PwMS.MethodsPwMS (n = 186) were prospectively assessed at three time points: baseline, 6 (Time 1) and 12 months later (Time 2). Clinical, demographic information and patient-reported medication beliefs, illness perceptions, medication habits, perceived health and affect were surveyed in-person. Adherence and persistence were assessed by a combination of self-reports and retrospective review of medication claims.FindingsPwMS were 69.9% (Time 1) and 71% (Time 2) adherent to their DMTs and 64.5.9% were persistent. Beliefs about Medications were consistently predictive at both time points (baseline to Time 1 and Time 1 to Time 2) of medication adherence and persistence whereas other perceptions were predictive in some analyses; clinical and demographic characteristics were mostly not predictive of adherence nor persistence. The prospective association of beliefs about medication with adherence held also in multivariate analyses (OR = 0.88, 95% CI 0.78–0.99, p = 0.029).ConclusionsAdherence and persistence are predicted by medication beliefs of PwMS. As medication beliefs are modifiable, they should be assessed periodically and targeted as a focus of tailored interventions aimed to improve adherence and consequently health outcomes in PwMS.RegistrationClinical trials registry #NCT02488343, date: 06/08/2015.

Highlights

  • Though adherence to disease-modifying therapies (DMTs) among persons with multiple sclerosis (PwMS) varies and is often below 80%, only few prospective studies on adherence examined predictors beyond demographic and clinical characteristics

  • Adherence and persistence are predicted by medication beliefs of PwMS

  • Despite of the long-term nature of the chronic condition that requires medication taking for long periods, the need for DMTs may be less obvious during periods of disease inactivity which may turn PwMS complacent on adherence

Read more

Summary

Introduction

Though adherence to disease-modifying therapies (DMTs) among persons with multiple sclerosis (PwMS) varies and is often below 80%, only few prospective studies on adherence examined predictors beyond demographic and clinical characteristics. There is widespread recognition that adherence to medication is key to successful health care of persons with Multiple Sclerosis (PwMS) [1,2,3,4,5] yet reviews on diseasemodifying therapies (DMT) medication-taking among PwMS estimate adherence as ranging between 41 and 88% [1] and persistence ranging from 16 to 27% [2]. Adherence refers to the extent of correspondence between medication-taking behavior and the recommendations made by the provider with respect to the timing, dosage, and frequency whereas persistence refers to staying on (same) treatment [11, 12]

Objectives
Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call